PRIA Logo™

The hidden hand

The Finnish antibody maker China now owns

HyTest controls the cardiac biomarker tests that diagnose heart attacks in hospitals worldwide—and has been a Chinese subsidiary since 2016.

The number

mostof world's cardiac emergency diagnostics

HyTest supplies the troponin I antibodies used to detect heart attacks from New York to London, but strategic control sits with Mindray Medical International, China's largest domestic medical device maker. The Finnish company continues operating under its Turku brand, masking Chinese corporate ownership of a critical diagnostic chokepoint.

Source: HyTest Ltd. — Antibody Manufacturing and Cardiac Marker Production · HyTest Ltd. · Jan 1, 2024

Jump into the supply map

Where this story connects

The supplymap lets you trace the goods, inputs, and companies this story touches — see the full dependency chain, country shares, and historical incidents.

Essential goods

Tap to see the full chain

Facilities

Tap for incidents + production

More on Producer · HyTest Ltd.

Related stories